23 December 2020: Clinical Research
Safety and Efficacy of Therapeutic Erythrocytapheresis Treatment in Chronic Mountain Sickness Patients in Shigatse, Tibet, China
Mingyuan Niu 1BCD* , Shekhar Singh 2EF* , Ma Mi 1B , Pian Bian 1B , Yawei Xu 2D , Zhuoga Deji 1AB* , Duoji Mima 1A* , Xiankai Li 2ACEG*DOI: 10.12659/MSM.927853
Med Sci Monit 2020; 26:e927853
Table 4 Echocardiographic measurement in CMS patient before and after TEA.
| Before TEA | After TEA | P value | |
|---|---|---|---|
| Diameter of (cm) | |||
| Left atrium | 3.2±0.5 | 3.3±0.5 | >0.05 |
| Left ventricle | 4.4±0.5 | 4.6±0.4 | |
| Right atrium | 3.7±0.8 | 3.6±0.5 | >0.05 |
| Right ventricle | 3.7±0.7 | 3.6±0.6 | >0.05 |
| Aorta (cm) | 3.0±0.4 | 3.0±0.4 | >0.05 |
| Pulmonary artery (cm) | 2.3±0.4 | 2.4±0.4 | >0.05 |
| Pulmonary pressure (mmHg) | 38.7±11.2 | 40.3±14.1 | >0.05 |
| LVEF (%) | 63±7 | 65±4 | >0.05 |
| LVFS (%) | 34±5 | 35±7 | >0.05 |
| LVEF – left ventricular ejection fraction; LVFS – Left ventricular fractional shortening. | |||